7:45 a.m.
Registration and Continental Breakfast
8:15 a.m.
Welcome
Michael A. Friedman, M.D., President and CEO, City of Hope
David Egal, Consul General of Israel in Los Angeles (not confirmed)
Sigal Admony-Ravid, Government of Israel Consul for Economic Affairs to the West Coast
8:30 a.m.
Overview
Richard Jove, Ph.D., Director, Beckman Research Institute, City of Hope
Ellen Feigal, MD. Ph.D., Vice President, Research and Development
California Institute for Regenerative Medicine
Innovative Partnerships for Advancing Stem Cell Science towards the Clinic
8:50 a.m.
Special Presentation
Dov Zipori, Ph.D., Weizmann Institute of Science (not confirmed)
Session I: Clinical Trials (and Tribulations) in Cell-based Therapies
9:10 a.m.
Karen Aboody, M.D., City of Hope
Neural stem cell-mediated cancer therapy: from bench to bedside
9:40 a.m.
Benjamin E. Reubinoff, M.D., Ph.D.
Hadassah Human Embryonic Stem Cell Research Center
Embryonic Stem Cells: from Bench to Patient
10:10 a.m.
BREAK
10:20 a.m.
Jane Lebkowski, Ph.D., Geron Inc. CA
TBD
10:50 a.m.
Tamir Ben-Hur, M.D., Ph.D., Hadassah-Hebrew University Medical Center
TBD
11:20 a.m.
John Zaia, M.D. Deputy Director for Clinical Research, City of Hope
Use of Stem Cells for Gene Therapy of AIDS: Current Status
11:50 a.m.
Zami Aberman, CEO, Pluristem Therapeutics
Placenta derived Stem Cells as Novel Therapy for Inflammatory and Ischemic Diseases
12:10 p.m.
Yael Margolin, Ph.D., Gamida Cell (not confirmed)
12:30 p.m.
LUNCH
1:30 p.m.
Special Presentation
Shosh Merchav Ph.D., Director, Cell Therapy Projects, TEVA Innovative Ventures
Overview of the Israeli Stem Cell Industry
Session II: Enabling Technologies – Bringing Discovery to Clinic
1:50 p.m.
Joseph Itskovitz-Eldor, M.D., DSc, Technion Israel Institute of Technology
TBD
2:10 p.m.
Phillip Gregory, Ph.D., Chief Scientific Officer, Sangamo BioSciences Inc.
Zinc finger nucleases: An enabling Technology for Stem Cell Therapy
2:30 p.m.
Arik Hasson Ph.D., VP Research and Development, Kadimastem Ltd.
Cutting edge technologies using stem cells for regenerative medicine and drug discovery
2:50 p.m.
John Foster, Ph.D., Chief Executive Officer, Owl Biomedical Inc.
A Clinical Cell Sorting System: Sterile, High Specificity, Easy to Use, and Scalable
3:10 p.m.
Nissim Benvenisty, M.D., Ph.D., Hebrew University
The study of genetic disorders using human pluripotent stem cells
3:30 p.m.
BREAK
Session III: Partnerships in Industry
3:40 p.m.
Duane Roth, Vice-Chair, Governing Board of CIRM, CEO of CONNECT
The distributed partnering model
4:00 p.m.
Yael Porat, Ph.D., Founder and CEO, BioGenCell
The Pros and Cons of Partnering with Stem Cell StartUps
4:20 p.m.
Alain Mir, Ph.D., Fluidigm Corporation
High-throughput, single-cell gene expression using microfuidic circuits
4:40 p.m.
Chris Airriess, Ph.D., California Stem Cell, Inc.
Patient-focused approaches to successful commercialization of regenerative medicine
5:00 p.m.
Mahendra Rao, M.D., Ph.D., Director, NIH Center for Regenerative Medicine, National Institutes of Health
TBD
5:20 p.m.
Q & A
5:35 p.m.
Concluding Remarks and Adjourment
